Skip to main content

Table 3 Characteristics of the 375 included studiesa

From: Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review

 

MI

Stroke

Stable angina

Unstable/unspecified angina

PAD

Revascularization

Total (across all CVDs)

Measure

Pre-2013

N (%)

Post-2013

N (%)

Pre-2013

N (%)

Post-2013

N (%)

Pre-2013

N (%)

Post-2013

N (%)

Pre-2013

N (%)

Post-2013

N (%)

Pre-2013

N (%)

Post-2013

N (%)

Pre-2013

N (%)

Post-2013

N (%)

Pre-2013

N (%)

Post-2013

N (%)

n

38

32

86

113

8

9

23

8

29

13

54

40

187

188

Method of elicitation

 EQ-5D

22 (57.9)

25 (78.1)

52 (60.5)

98 (86.7)

6 (75.0)

8 (88.9)

13 (56.5)

7 (87.5)

21 (72.4)

12 (92.3)

46 (85.2)

36 (90.0)

124 (66.3)

166 (88.3)

 HUI

4 (10.5)

1 (3.1)

9 (10.5)

2 (1.8)

0 (0)

0 (0)

0 (0)

0 (0)

5 (17.2)

0 (0)

5 (9.3)

0 (0)

19 (10.2)

2 (1.1)

 SF-6D

2 (5.3)

3 (9.4)

6 (7.0)

6 (5.3)

2 (25.0)

3 (33.3)

3 (13.0)

0 (0)

2 (6.9)

1 (7.7)

5 (9.3)

4 (10.0)

14 (7.5)

15 (8.0)

 SG

2 (5.3)

1 (3.1)

12 (14.0)

3 (2.7)

2 (25.0)

1 (11.1)

3 (13.0)

0 (0)

6 (20.7)

0 (0)

4 (7.4)

0 (0)

24 (12.8)

4 (2.1)

 TTO

5 (13.2)

2 (6.2)

11 (12.8)

3 (2.7)

1 (12.5)

1 (11.1)

4 (17.4)

1 (12.5)

8 (27.6)

0 (0)

7 (13.0)

0 (0)

27 (14.4)

4 (2.1)

 Othersb

6 (15.8)

2 (6.2)

6 (7.0)

3 (2.7)

1 (12.5)

1 (11.1)

3 (13.0)

0 (0)

6 (20.7)

0 (0)

2 (3.7)

2 (5.0)

19 (10.2)

6 (3.2)

Type of respondent

 Patients

37 (97.4)

30 (93.8)

84 (97.7)

107 (94.7)

7 (87.5)

8 (88.9)

22 (95.7)

6 (75.0)

29 (100.0)

13 (100.0)

54 (100.0)

40 (100.0)

183 (97.9)

181 (96.3)

 General population

1 (2.6)

2 (6.2)

3 (3.5)

5 (4.4)

1 (12.5)

1 (11.1)

1 (4.3)

2 (25.0)

0 (0)

0 (0)

0 (0)

0 (0)

5 (2.7)

6 (3.2)

 Caregivers

0 (0)

0 (0)

3 (3.5)

2 (1.8)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

3 (1.6)

2 (1.1)

 Mixed

0 (0)

0 (0)

3 (3.5)

2 (1.8)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

3 (1.6)

2 (1.1)

Study design

 Trial

9 (23.7)

14 (43.8)

10 (11.6)

37 (32.7)

2 (25.0)

3 (33.3)

2 (8.7)

2 (25.0)

12 (41.4)

4 (30.8)

18 (33.3)

20 (50.0)

42 (22.5)

70 (37.2)

 Survey

16 (42.1)

10 (31.2)

34 (39.5)

28 (24.8)

4 (50.0)

3 (33.3)

16 (69.6)

4 (50.0)

5 (17.2)

4 (30.8)

6 (11.1)

4 (10.0)

56 (29.9)

39 (20.7)

 Prospective cohort

9 (23.7)

4 (12.5)

31 (36.0)

37 (32.7)

1 (12.5)

2 (22.2)

2 (8.7)

1 (12.5)

7 (24.1)

4 (30.8)

25 (46.3)

12 (30.0)

67 (35.8)

59 (31.4)

 Retrospective cohort

1 (2.6)

4 (12.5)

5 (5.8)

8 (7.1)

0 (0)

0 (0)

0 (0)

1 (12.5)

5 (17.2)

1 (7.7)

4 (7.4)

5 (12.5)

13 (7.0)

17 (9.0)

 Others (analysis, NR)

3 (7.9)

0 (0)

6 (7.0)

3 (2.7)

1 (12.5)

1 (11.1)

3 (13.0)

0 (0)

1 (3.4)

0 (0)

1 (1.9)

0 (0)

10 (5.3)

4 (2.1)

Geographic region

 Europe

16 (42.1)

15 (46.9)

40 (46.5)

51 (45.1)

4 (50.0)

4 (44.4)

9 (39.1)

2 (25.0)

22 (75.9)

7 (53.8)

33 (61.1)

15 (37.5)

92 (49.2)

83 (44.1)

 US and Canada

14 (36.8)

4 (12.5)

27 (31.4)

17 (15.0)

1 (12.5)

1 (11.1)

10 (43.5)

2 (25.0)

5 (17.2)

3 (23.1)

8 (14.8)

7 (17.5)

53 (28.3)

27 (14.4)

 Asia

1 (2.6)

5 (15.6)

6 (7.0)

30 (26.5)

2 (25.0)

2 (22.2)

1 (4.3)

3 (37.5)

0 (0)

2 (15.4)

3 (5.6)

5 (12.5)

11 (5.9)

39 (20.7)

 Othersc

7 (18.4)

8 (25.0)

13 (15.1)

21 (18.6)

1 (12.5)

2 (22.2)

4 (17.4)

1 (12.5)

2 (6.9)

2 (15.4)

12 (22.2)

13 (32.5)

33 (17.6)

46 (24.5)

  1. aPercentages may add to > 100% for utility method, respondent, or geographic region, as some studies reported utility values in more than 1 category (ie, a study that compared EQ-5D to SF-6D would count in both categories)
  2. bOther methods include Quality of Well-Being, Utility Based Quality of life-Heart questionnaire, Assessment of Quality of Life, and Preference-based Stroke Index
  3. cOthers include studies conducted in Australia, Brazil, Israel, Mexico, New Zealand, Nigeria, and Zimbabwe, as well as studies conducted in multiple regions or those that did not report geography
  4. Abbreviations: CVD Cardiovascular disease, EQ-5D EuroQol Five Dimensions Questionnaire, HUI Health Utilities Index, MI Myocardial infarction, NR Not reported, PAD Peripheral artery disease, SF-6D Short-Form Six Dimensions, SG Standard gamble, TTO Time trade-off, US United States
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us